BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rayner CR, Smith PF, Hershberger K, Wesche D. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders. Clin Transl Sci 2020;13:830-4. [PMID: 32212378 DOI: 10.1111/cts.12790] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 van der Graaf PH, Giacomini KM. COVID-19: A Defining Moment for Clinical Pharmacology? Clin Pharmacol Ther 2020;108:11-5. [PMID: 32350861 DOI: 10.1002/cpt.1876] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Venisse N, Peytavin G, Bouchet S, Gagnieu MC, Garraffo R, Guilhaumou R, Solas C; ANRS-AC43 Clinical Pharmacology Committee, SFPT Therapeutic Drug Monitoring and Treatment Personalization group. Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection. Antiviral Res 2020;181:104866. [PMID: 32659293 DOI: 10.1016/j.antiviral.2020.104866] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
3 Hui S. Recent scientific research progress and challenges of COVID-19 pandemic: a global public health event. Proc Indian Natl Sci Acad 2021;87:547-61. [DOI: 10.1007/s43538-021-00058-x] [Reference Citation Analysis]
4 Davda J, Reynolds K, Davis JD, Smith PF. Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics. Br J Clin Pharmacol 2021;87:3398-407. [PMID: 33855747 DOI: 10.1111/bcp.14859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Infect Genet Evol 2020;83:104327. [PMID: 32320825 DOI: 10.1016/j.meegid.2020.104327] [Cited by in Crossref: 128] [Cited by in F6Publishing: 97] [Article Influence: 64.0] [Reference Citation Analysis]
6 Rayner CR, Smith PF, Andes D, Andrews K, Derendorf H, Friberg LE, Hanna D, Lepak A, Mills E, Polasek TM, Roberts JA, Schuck V, Shelton MJ, Wesche D, Rowland-Yeo K. Model-Informed Drug Development for Anti-Infectives: State of the Art and Future. Clin Pharmacol Ther 2021;109:867-91. [PMID: 33555032 DOI: 10.1002/cpt.2198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Patel K, Dodds M, Gonçalves A, Kamal MA, Rayner CR, Kirkpatrick CM, Smith PF. Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: An example in SARS-CoV-2. Br J Clin Pharmacol 2021;87:3425-38. [PMID: 33373059 DOI: 10.1111/bcp.14718] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]